Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of ADC Therapeutics's ADCT-602?
ADCT-602 is a monoclonal antibody conjugated commercialized by ADC Therapeutics, with a leading Phase II program in B-Cell Acute Lymphocytic...
Data Insights
ADCT-602 by ADC Therapeutics for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
ADCT-602 is under clinical development by ADC Therapeutics and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute...